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Abstract 
Peroxisomes are single membrane bound organelles present in almost all eukaryotic cells, 
and to date have been shown to contain approximately 60 identified enzymes involved in 
various metabolic pathways, including the oxidation of a variety of lipids. These lipids 
include very long-chain fatty acids, methyl branched fatty acids, prostaglandins, bile acid 
precursors, and xenobiotics that are either β-oxidized or α-oxidized in peroxisomes. The 
recent identification of several acyl-CoA thioesterases and acyltransferases in 
peroxisomes has revealed their various functions in acting as auxiliary enzymes in α- and 
β-oxidation in this organelle. To date, 9 functional acyl-CoA thioesterases and 
acyltransferases have been identified in mouse and 4 functional acyl-CoA thioesterases  
and acyltransferases in human, thus these enzymes make up a substantial portion of 
peroxisomal proteins.  This review will therefore focus on new and emerging roles for 
these enzymes in assisting with the oxidation of various lipids, amidation of lipids for 
excretion from peroxisomes, and in controlling coenzyme A levels in peroxisomes.  
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1. Introduction 
 
Peroxisomes are nearly ubiquitous organelles present in fungi, yeast, plant and animal 
cells. The peroxisome received its name in the 1960’s from the pioneering work of 
Christian de Duve and co-workers [1]. The discovery by Goldfischer et al. in 1973 that 
peroxisomes are involved in certain human diseases [2] paved the way for the discovery 
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of the importance of peroxisomes in the oxidation of various types of lipid molecules. 
One of the milestones in peroxisome research was the identification of a fatty acid β-
oxidation system in mammalian peroxisomes (distinct from the mitochondrial β-
oxidation system), and this led to a boost in research that revealed a discrete set of 
enzymes that catalyze the degradation of a variety of lipids (for reviews see [3-5]). These 
studies showed that rat and mouse liver peroxisomes contain three acyl-CoA oxidases 
which identified separate pathways for β-oxidation of different lipids in peroxisomes. 
These acyl-CoA oxidases catalyze the β-oxidation of straight-chain acyl-CoAs (catalyzed 
by acyl-CoA oxidase 1, ACOX1), β-oxidation of the side-chain of bile acid precursors 
(catalyzed by ACOX2) and methyl branched-chain CoA esters (catalyzed by ACOX3). It 
is now well established that peroxisomes have many metabolic roles including β-
oxidation, α-oxidation, glyoxylate metabolism, ether-phospholipid synthesis, cholesterol 
and isoprenoid metabolism and bile acid synthesis. There are numerous existing reviews 
regarding the biochemistry of peroxisomes, peroxisome biogenesis and peroxisomal 
disorders [6-11], therefore these aspects will not be discussed in detail in this review. The 
recent identification and characterization of acyl-CoA thioesterases (ACOTs) and 
acyltransferases has now established distinct roles for these enzymes in peroxisomes and 
the current review will focus on these novel functions of these proteins as auxiliary 
enzymes in peroxisomal lipid metabolism. There are currently six ACOTs characterized 
in mouse peroxisomes, but only two in human peroxisomes. A family of related 
acyltransferases has also been identified in mouse and rat peroxisomes, with three 
acyltransferases in mouse, whereas human peroxisomes contain only one functional 
acyltransferase. This review will firstly focus on the identification of these enzymes, 
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followed by a discussion as to their metabolic functions as auxiliary enzymes in 
peroxisomes.  A list of currently identified ACOT and acyltransferase enzymes in mouse 
and human peroxisomes are given in Table I and II respectively, together with the current 
and previous nomenclature, tissue expression and substrate specificity. 
 
2. Identification and characterization of acyl-CoA thioesterases in peroxisomes 
 
2.1 Characterization of peroxisomal acyl-CoA thioesterases 
 
ACOT activity was first identified as early as the 1950’s, with the partial purification of a 
succinyl-CoA thioesterase from pig heart [12]. Since then several different families of 
ACOTs have been identified and characterized, as reviewed in [13]. As these genes were 
cloned by various groups, they were all given different names which led to confusion, 
and therefore a recent nomenclature has been introduced, in which the gene name is Acot 
and the genes are numbered sequentially [14]. The reaction carried out by ACOTs 
involves the cleavage of the thioester bond of acyl groups attached to coenzyme A, to 
release the free acid and free CoASH (Fig. 1A). The acyl group can vary and have been 
identified as long-, medium- and short-chain fatty acids, dicarboxylic acids, branched 
chain fatty acids or bile acids, depending on the ACOT enzyme involved. The second 
group of enzymes reviewed here are the acyl-CoA:amino acid N-acyltransferases, which 
catalyze the transfer of carboxylic acids from CoASH to an amino acid, usually taurine or 
glycine (Fig. 1B and 1C). 
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2.1.1 The Type-I family of acyl-CoA thioesterases 
Initial interest in ACOT activity in rodent stems from the findings that the activity is 
highly inducible in livers of rats treated with peroxisome proliferators, such as fibrates 
that act as hypolipidemic agents. Subcellular fractionation of rat livers showed that the 
activity is mainly increased in mitochondria, cytosol and peroxisomes by these 
compounds [15-18]. Peroxisome proliferators act as hypolipidemic agents in part by 
increasing fatty acid degradation via activation of peroxisome proliferator-activated 
receptor alpha (PPARα), which is a lipid activated transcription factor that is a key 
regulator of genes involved in fatty acid metabolism [19]. The increase in ACOT activity 
by PPARα activators suggested that these enzymes may be beneficial for fatty acid 
degradation (regulation of expression of the ACOT enzymes will be discussed in more 
detail in section 5). Biochemical analysis of highly purified peroxisomes revealed ACOT 
activity with short, medium and long-chain acyl-CoAs (from C2-C20-CoA) [20, 21] and 
partial purification of a peroxisomal ACOT revealed a long-chain acyl-CoA thioesterase 
activity [20]. A similar long-chain ACOT activity was purified from rat liver 
mitochondria and cytosol and at that time, an antibody raised against a purified 
mitochondrial acyl-CoA thioesterase (ACOT2, formerly known as MTE-I), identified 
structurally related proteins in mitochondria, cytosol and peroxisomes, suggesting a 
related protein family [22, 23]. In the genomic era, the cloning of specific genes was 
carried out, which resulted in the identification of several distinct peroxisomal acyl-CoA 
thioesterases. One particular gene family that was identified at that time was named the 
Type-I acyl-CoA thioesterase gene family, which based on enzyme activity 
measurements and Western blot analysis was suggested to code for closely related 
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enzymes in cytosol, mitochondria and peroxisomes [20, 22]. Subsequent molecular 
cloning of this gene family identified a cluster of six related genes, localized on 
chromosome 12 D3 in mouse [24-27] (Fig. 2). Four of these six genes code for enzymes 
that localize in peroxisomes as they all contain peroxisomal type 1 targeting signals 
(PTS1) at their carboxyterminal ends. In mouse, these four peroxisomal acyl-CoA 
thioesterases are named ACOT3, 4, 5 and 6, which show approximately 65-80% 
sequence identity to eachother. These four proteins end –AKL (ACOT3 and ACOT5), -
CRL (ACOT4) and –SKL (ACOT6) (Fig. 2), which targets them to peroxisomes as 
confirmed in all cases using green fluorescent fusion protein experiments [25-27]. The 
open reading frames of all four genes are encoded by three exons and the exon/intron 
boundaries are conserved in this gene family. The ACOT3 and ACOT5 show the highest 
degree of sequence similarity (82%) and were therefore characterized simultaneously in a 
study in 2004 [26]. Expression of the recombinant proteins revealed that ACOT3 is a 
long chain acyl-CoA thioesterase (highest activity with C14 – C18-CoA, whereas ACOT5 
is a medium chain acyl-CoA thioesterase (highest activity with C10-CoA). Interestingly, 
ACOT3 and ACOT5 had little or no activity towards 3-hydroxy-palmitoyl-CoA, an 
intermediate in peroxisomal β-oxidaiton, suggesting that these enzymes hydrolyze the 
substrates/products of β-oxidaiton, but not intermediates in the pathway [26]. Acot3 
mRNA is expressed as two splice variants, which show a tissue-specific expression in 
liver and kidney [26]. In contrast, Acot5 is mainly expressed in white adipose tissue and 
brain [28].  
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The ACOT4 shows the lowest percentage sequence similarity to the other peroxisomal 
thioesterases (65%) and indeed was the first thioesterase to reveal a more ‘specific’ 
substrate specificity, being active only with succinyl-CoA (Km ≈13 µM) and glutaryl-CoA 
(Km ≈37 µM) [25], suggesting a role in dicarboxylic acid metabolism. The mouse Acot4 
mRNA is expressed mainly in liver, kidney and proximal intestine, with the former two 
organs being involved in dicarboxylic acid formation and metabolism. Interestingly, 
analysis of the gene cluster of the human Type-I ACOT genes revealed only one 
functional peroxisomal gene, encoded for by a homologue of mouse Acot4, which 
contains a carboxyterminal –PKL and is localized in peroxisomes (Fig. 2) [29]. This was 
a surprising finding, given that the mouse genome contained four peroxisomal Type-I 
ACOTs. However, functional analysis revealed that the human ACOT4 protein could in 
fact catalyze the hydrolysis of the same substrates as the combined activities of mouse 
ACOT3, ACOT4 and ACOT5 (i.e. long-chain acyl-CoAs, succinyl-CoA/glutaryl-CoA 
and medium-chain acyl-CoAs) [29], showing that evolution of the human genome 
resulted in an enzyme that apparently adopted the activities of three distinct mouse 
enzymes. In human, analysis of the genome also revealed the presence of a further gene 
on chromosome 19q13.12, which showed 91% sequence identity to the human ACOT4 
gene and contains a peroxisomal targeting signal of -PKL. However, this gene on 
chromosome 19 lacks introns and contains several stop codons, and is therefore likely a 
pseudogene, even though the mRNA is expressed as identified by ESTs in pancreatic 
islets, brain and placenta [29]. 
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The final peroxisomal enzyme encoded for by the Type-I gene cluster in mouse was 
recently identified as ACOT6, a thioesterase that is apparently only active on phytanoyl-
CoA and pristanoyl-CoA [27]. The corresponding mRNA is mainly expressed in white 
adipose tissue, where it is co-expressed with Acox3, the rate-limiting enzyme in branched 
chain acyl-CoA oxidation. In human, there is a homologue of the mouse Acot6, which is 
however unlikely to code for a functional protein as this gene appears to be transcribed 
from the second exon, and translated from an ATG at the end of exon 2, therefore 
resulting in a much shorter peptide [29]. The human ACOT6 contains a carboxyterminal 
tripeptide of –SKI, which localizes in the cytosol in human skin fibroblasts, when fused 
to green fluorescent protein [29].  
 
Searches in databases suggest that homologues of these Type-I family of Acot genes are 
widespread in animals from nematodes to human, but are not found in yeast, fungi, plants 
or insects. Sequence analysis, secondary structure predictions and site-directed 
mutagenesis experiments identified the Type-I ACOTs as members of the α/β-hydrolase 
protein superfamily, members of which contain a lipase/esterase active site motif that is 
characterized by a conserved serine residue located in a GlyXaaSerXaaGly motif 
(GxSxG) [30]. In addition these α/β-hydrolases contain a conserved histidine residue and 
an aspartic/glutamic acid residue, which together with the nucleophile constitute a 
catalytic triad in this protein family.  
 
2.1.2. ACOT8 is a peroxisomal ACOT with very broad substrate specificity and possibly 
functions in regulation of intraperoxisomal CoASH levels 
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A further peroxisomal acyl-CoA thioesterase named ACOT8, (previously known as PTE-
2, PTE1 or hACTEIII/hTE), has also been characterized, which is not related to the Type-
I gene family discussed above. This enzyme was initially identified by a yeast two-hybrid 
screening as a protein that interacted with, and activated, the HIV-1 Nef protein [31, 32]. 
Nef is a 27-kDa myristoylated cytoplasmic protein that is involved in CD4 down-
regulation and it was suggested that interaction of ACOT8 and Nef assisted in mediation 
of Nef-induced CD4 down-regulation. Nef is not a bona fide peroxisomal protein, but 
apparently “piggy-backs” into peroxisomes by interacting with ACOT8, although only in 
about 10-20% of the cells examined [33]. The human ACOT8 and its yeast counterpart 
Pte1 were identified by Jones et al. in 1999 as peroxisomal proteins, and deletion of the 
yeast Pte1 resulted in impaired growth on fatty acids, implying a role for this gene in 
fatty acid oxidation [34]. The yeast Pte1 had significant thioesterase activity with 
decanoyl-CoA, however the substrate specificity was not studied for the human enzyme 
at this time. It is of interest to note that knockdown of the Pte1 in yeast resulted in the 
loss of about 80% of the decanoyl-CoA thioesterase activity in yeast extracts, suggesting 
that Pte1 accounts for the majority of the thioesterase activity in yeast. The yeast Pte1 
was further characterized by Maeda et al in 2006 and shown to hydrolyze short and 
medium straight chain and branched chain acyl-CoAs, and thereby was shown be 
involved in synthesis of polyhydroxy-alkanoates (PHA) and in β-oxidation in yeast [35]. 
In Arabidopsis thaliana, the ACOT8 homologue, called ACH2, contains a 
carboxyterminal –SKL and is therefore likely also a peroxisomal enzyme [36]. The 
cloned A. thaliana enzyme is active on long-chain saturated and unsaturated acyl-CoAs, 
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but was insensitive to feedback inhibition by CoA even up to 100 µM, and it was 
suggested that ACH2 is unlikely to have a role in fatty acid oxidation in plants. Yeast 
does not contain any homologues to the Type-I ACOTs or ACOT12 (described in section 
2.1.3), and therefore it is likely that the only yeast peroxisomal thioesterase is Pte1. 
 
Further characterization of the ACOT8 enzyme in mouse and rat identified it as an acyl-
CoA thioesterase, which hydrolyzes a very wide variety of CoASH esters [25, 37, 38]. In 
fact ACOT8 hydrolyzes all acyl-CoA esters tested so far, indicating that this enzyme 
likely recognizes the CoA moiety of the substrate for binding and not the acyl-chain. In 
support of this, to date ACOT8 is one of only two peroxisomal ACOT enzymes regulated 
by free CoASH with an estimated IC50 of ~10-15 µM [37]. As the human ACOT8 
enzyme shows about 80% sequence identity to the rat [38] and mouse [37] enzymes, it is 
likely that the human ACOT8 also hydrolyzes a wide variety of acyl-CoA substrates. 
Interestingly, over-expression of human ACOT8 in murine and human T-cell lines 
resulted in an up-regulation of peroxisomal biogenesis, further supporting a link between 
metabolic activity and peroxisome proliferation [39]. Crystallization of the Escherichia 
coli homolog of ACOT8 (E. coli thioesterase II) identified a ‘double hot dog’ tertiary 
fold, with a novel catalytic site containing aspartic acid, glutamine and threonine [40]. 
This is in fact one of the few crystal structures currently available for homologues of the 
mammalian ACOT enzymes, however work is currently underway to crystallize several 
of these mammalian proteins. In E. coli however, there are seven different hot dog 
thioesterases encoded by the E. coli genome that have a known X-ray structure, the 
biological function is only known in the case of one thioesterase [41]. 
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2.1.3 ACOT12 is a short-chain ACOT that may be involved in acetate formation from 
peroxisomal β-oxidation 
 
ACOT12 is the most recently identified peroxisomal ACOT, which is active on short 
chain acyl-CoAs. This enzyme was originally identified as an extra-mitochondrial short 
chain thioesterase with highest activity with acetyl-CoA, and some activity also with 
butyryl-CoA and hexanoyl-CoA [42-44]. ACOT12 is a protein of 555 amino acids in 
human (556 in mouse), and mouse and rat proteins contain a variant of the type 1 
peroxisomal targeting signal of –SVL. However, the carboxyterminal of human ACOT12 
ends –STF [45], suggesting that in rodents the protein is peroxisomal, but this may not be 
the case in human. Previous work using subcellular fractionation and Western blotting 
revealed the protein and activity in peroxisomal fractions in rat liver, suggesting that 
ACOT12 is indeed a peroxisomal protein, or that at least it may have a dual localization 
in peroxisomes and cytosol [46]. In addition, a very recent proteomics study on mouse 
kidney peroxisomes also identified ACOT12 in peroxisomes [47]. ACOT12 shows some 
interesting features that clearly distinguishes it from the other peroxisomal ACOTs. 
ACOT12 is a 62 kDa protein that contains two thioesterase domains with homology to 
bacterial thioesterases and some other mammalian ACOTs (but not to the Type-I 
ACOTs), and a C-terminal part that contains a steroidogenic acute regulatory protein-
related lipid transfer (START) domain [45], which is likely to be involved in lipid 
binding. The enzyme appears to be an acetyl-CoA thioesterase, with lower activities with 
propionyl-CoA and butyryl-CoA [42]. Also, the enzyme activity is activated by ATP and 
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inhibited by ADP [48] indicating a possible metabolic regulation of acetate production by 
nucleotide levels in peroxisomes. The rat ACOT12 enzyme is also inhibited by free 
CoASH (approx. 80% inhibition at 40 µM, IC50 approx 10 µM) [48], making ACOT12 
and ACOT8 the only two peroxisomal thioesterases currently identified that are regulated 
by free CoASH.  
 
In summary of the above, mouse contains six currently characterized peroxisomal 
ACOTs, namely ACOT3, ACOT4, ACOT5, ACOT6, ACOT8 and ACOT12, whereas 
human contains only two, ACOT4 and ACOT8. The revised nomenclature and the 
substrate specificities of these enzymes is shown in Table I (mouse) and Table II 
(human). It is intriguing that in particular rodents contain a number of ACOTs with 
distinct substrate specificities, which indicate that these enzymes play important roles in 
regulation of peroxisomal lipid metabolism. 
 
 
3. Role of acyl-CoA thioesterases as auxiliary enzymes in regulation of peroxisomal 
α- and β- oxidation 
3.1 An overview of peroxisomal β-oxidation 
Peroxisomal β-oxidation of carboxylic acids is generally believed to act as a chain-
shortening system and thereby provide mitochondria with suitable substrates. 
Alternatively, the peroxisomal β-oxidation may be considered to function as a 
detoxification system to metabolize carboxylic acids into more water-soluble products 
that can be excreted. In addition to the physiological CoA esters that undergo β-oxidation 
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in peroxisomes, such as very long-chain fatty acids, bile acid intermediates, eicosanoids,  
and methyl branched fatty acids, also some xenobiotic carboxylic acids undergo β-
oxidation in peroxisomes (for review, see [49]). Most of the carboxylic acids are 
activated to the corresponding CoA ester outside the peroxisome by acyl-CoA 
synthetases localized in the peroxisomal membrane or in the endoplasmic reticulum [50], 
and most likely the CoA ester is being transported across the peroxisomal membrane via 
a family of ATP-binding-casette transporters (ABC transporters). To date, four 
peroxisomal ABC half-transporters have been identified, which have been recently 
discussed in detail in a mini-review by Kemp et al [51]. ABCD1 is involved in the 
transport of very long chain acyl-CoAs into peroxisomes and mutations in this protein 
result in X-linked adrenoleukodystrophy [52]. ABCD3 is proposed to be involved in 
transport of long chain acyl-CoAs [53], but recently, unpublished data referred to in [54] 
stated that Abcd3-knockout mice were found to accumulate bile acid precursors and 
branched chain fatty acids, suggesting that this transporter may be involved in transfer of 
these CoA esters into the peroxisome. Inside the peroxisomal matrix, there is a dedicated 
set of enzymes that β-oxidize these CoA esters. The first step in peroxisomal β-oxidation 
is carried out by an acyl-CoA oxidase (ACOX), and rodents contain three acyl-CoA 
oxidase enzymes [55-57], which dehydrogenate straight-chain acyl-CoAs, branched chain 
acyl-CoAs and the bile acid intermediates trihydroxycoprostanoyl-CoA and 
dihydroxycoprostanoyl-CoA, respectively. Human contains only two ACOX enzymes 
catalyzing straight-chain and branched-chain acyl-CoA dehydrogenation, respectively 
[58, 59]. The second and third steps in peroxisomal β-oxidation are catalyzed by 
multifunctional enzymes MFP1 or MFP2 (L- or D- bifunctional proteins) [60-62]. The 
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final step in peroxisomal β-oxidation involves a thiolytic cleavage of the acyl-CoA 
catalyzed by either 3-ketoacyl-CoA thiolases a or b, or SCPx [63-65], resulting in the 
release of a chain-shortened acyl-CoA and acetyl-CoA or propionyl-CoA, depending on 
the substrate initially oxidized. The 2 carbon acetyl-CoA is released during the β-
oxidation of very long chain acyl-CoAs, branched chain acyl-CoAs and dicarboxylyl-
CoAs, whereas propionyl-CoA is released during β-oxidation of branched chain acyl-
CoAs and bile acid intermediates.  
 
As stated above, the peroxisomal β-oxidation of substrates results in chain-shortening of 
carboxylic acids, with the concomitant release of acetyl-CoA or propionyl-CoA, and 
hence the peroxisome requires a system to remove fatty acids from the β-oxidation 
process. There are three possible routes for the removal of fatty acids, namely formation 
of carnitine esters, which can be transferred to mitochondria for further oxidation, 
conjugation to glycine/taurine by acyltransferases (e.g. bile acid and fatty acid 
conjugation) for excretion into bile or blood, or alternatively hydrolysis to the free acid 
by ACOT enzymes for transport to mitochondria or excretion in urine. The involvement 
of ACOTs, carnitine acyltransferases and acyl-CoA:amino acid N-acyltransferases in 
these routes is shown in Fig. 3 and will be discussed below. 
 
3.1.1 Peroxisomes contain lipid-binding proteins that influence ACOT activity and β-
oxidation. 
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Peroxisomes contain two lipid-binding proteins that potentially provide additional 
regulation to peroxisomal fatty acid metabolism. Almost 30 years ago, sterol carrier 
protein-2 (SCP2) was purified as a soluble sterol carrier, but was later shown to localize 
to peroxisomes via a PTS1 signal. Several findings since then have changed the view on 
the function of SCP2 in peroxisomal lipid metabolism, as reviewed in [66]. Subsequent 
characterization of the functions of this protein in various experimental systems suggest 
that SCP2 may act as an acyl-CoA binding protein that can interact with enzymes of the 
peroxisomal β-oxidation system. This could serve several purposes, for example delivery 
of acyl-CoA’s to the degradation pathway, which may provide a mechanism for increased 
efficiency for  fatty acid oxidation in peroxisomes and possibly also protect acyl-CoAs’ 
from hydrolysis by ACOT’s. Very recently Antonenkov et al showed that in addition to 
it’s well known cytosolic localization, the liver fatty acid binding protein (L-FABP) is 
also a bona fide peroxisomal protein [67]. Although it appears that only a small fraction 
of L-FABP is present in peroxisomes under normal (control) conditions, the amount is 
strongly increased by fibrate treatment. It was also demonstrated that addition of purified 
L-FABP to isolated peroxisomes stimulated β-oxidation of palmitoyl-CoA at higher 
substrate concentrations, presumably preventing substrate inhibition. Similarly, ACOT 
activity was also stimulated by the addition of L-FABP, probably via a similar 
mechanism by preventing substrate inhibition. The presence in peroxisomes of lipid 
binding proteins and the ACOT’s point to regulatory functions for these proteins in 
peroxisomal lipid metabolism, but it is not yet known how these proteins interact. 
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3.2 Acyl-CoA thioesterases and carnitine acyltransferases are differently expressed and 
may promote production of different metabolites in different organs. 
 
Peroxisomes contain ACOTs and carnitine acyltransferases with similar acyl-CoA 
substrate specificities, which raises questions as to their roles in fatty acid metabolism. 
Carnitine acyltransferases are a group of enzymes that catalyze the reversible transfer of 
acyl-CoAs of varying chain-lengths to carnitine. Peroxisomes contain two distinct 
carnitine acyltransferases, carnitine octanoyltransferase (CROT) and carnitine 
acetyltransferase (CRAT) [68, 69], and it was generally believed that formation of 
carnitine esters was the terminal reaction in peroxisomes to produce shorter metabolites 
that could be transported to mitochondria for further oxidation. CROT catalyzes the 
transfer of medium chain (C6-C10) acyl-CoAs and methyl branched medium-chain acyl-
CoAs, such as dimethylnonanoyl-CoA (DMN-CoA), to carnitine [70, 71]. CRAT has 
been characterized as a short chain carnitine acyltransferase, with highest activity with 
butyryl-CoA, followed by propionyl-CoA and acetyl-CoA [71]. CRAT purified from 
mouse liver has a Km of ≈ 20 µM with short chain acyl-CoA’s, whereas CROT has a Km 
of ≈ 3.4 µM with medium-chain acyl-CoAs (up to C12-CoA) and a higher Km towards 
longer chain acyl-CoAs [71]. 
  
The recent identification of ACOT’s with distinct acyl-CoA specificities challenges this 
view and suggests that the free acids may also be terminal metabolites in peroxisomes. 
Peroxisomes contain two acyl-CoA thioesterases (ACOT12 and ACOT5), which are 
specific for short- and medium-chain acyl-CoA’s respectively. Mouse ACOT5 was 
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identified as a medium chain acyl-CoA thioesterase, preferentially hydrolyzing C8-C12 
acyl-CoAs, with a Km value of ≈ 3 µM [26]. In addition to ACOT5, ACOT8 hydrolyzes 
short- and medium-chain acyl-CoAs, with Km-values of 3-30 µM depending on the 
substrate [37]. Peroxisomes contain the short chain acyl-CoA thioesterase ACOT12 as 
described in Section 2.1.3., which hydrolyzes short chain acyl-CoAs with a Km of 60 -200 
µm [42, 43]. The presence of short and medium chain acyl-CoA thioesterases and 
carnitine acyltranserases in peroxisomes suggests that these enzymes would compete for 
the same substrate but produce different metabolites (ACOTs producing the free acid and 
the carnitine acyltransferases producing carnitine esters). However, a recent study into 
the mRNA expression of the acyltransferase and acyl-CoA thioesterase enzymes shows 
that these enzymes have in fact a very different tissue expression profile [28]. Therefore, 
depending on the tissue, either the free acid will be produced (by thioesterases) or the 
carnitine ester (by carnitine acyltransferases), suggesting that two complementary 
enzyme systems exist for the removal of acyl-CoA esters from the peroxisome rather than 
being competitive enzymes for the same substrate (Fig. 4). In line with this, it has been 
shown that peroxisomal β-oxidation in liver (studied in cultured hepatocytes) results in 
the production of free acetate [72] whereas in heart, free acetate does not appear to be a 
major metabolite produced by peroxisomal β-oxidation [73]. These findings can be 
explained by the different tissue expression of Crat and Acot12, since Acot12 is mainly 
expressed in liver, whereas Crat is expressed at very low levels in this tissue [28], thus 
resulting mainly in production of acetate in liver. In contrast, in heart the expression of 
Crat dominates, likely resulting in carnitine ester production for transfer to mitochondria, 
and less acetate production. This aspect of carnitine acyltransferase versus acyl-CoA 
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thioesterase routes for production of carnitine esters or free acids has also recently been 
addressed by Wanders & Komen, who suggested that in liver the thioesterase pathway is 
likely to dominate, whereas in human skin fibroblasts, production of carnitine esters is 
the most important route [74]. It should also be kept in mind that the relative importance 
of the free acid and carnitine ester pathways may depend on the physiological conditions 
regarding the degree of sequestration of CoASH, which will also regulate the activity of 
ACOT8 and ACOT12. However, a further obvious function for CRAT may also be to 
transfer butyryl-CoA (which cannot be β-oxidized in peroxisomes) [75] to carnitine for 
further transport to mitochondria.  
 
It is well established that peroxisomes also contain the medium-chain enzymes carnitine 
octanoyltransferase (CROT) and ACOT5, which would play similar roles to produce 
carnitine esters versus free acids, but using medium chain acyl-CoA’s. Indeed CROT was 
recently demonstrated to transfer DMN-CoA (formed during β-oxidation of branched 
chain fatty acids) to DMN-carnitine, which can be transferred to the mitochondria for 
further oxidation [70]. The CROT enzyme is most highly expressed in liver and the 
proximal intestine, followed by kidney, with much lower expression in other tissues [28]. 
Again, the thioesterase (Acot5) shows a different tissue expression pattern, being most 
highly expressed in white adipose tissue and brain. These data therefore suggest that 
medium chain acyl-CoA’s produced in peroxisomes in liver and intestine will be 
transferred to carnitine esters and presumably further on to mitochondria (Fig. 4). The 
importance of esterification to carnitine for transfer to mitochondria is not obvious in 
view of the fact that medium chain fatty acids apparently enter mitochondria in a 
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carnitine independent manner, suggesting that medium chain fatty acids generated from 
the action of Acot5 could also be transferred to mitochondria. However, the strikingly 
different tissue expression pattern of Acot5, being most highly expressed in white adipose 
tissue and brain, suggests more specific functions for this enzyme in these tissues. 
 
3.2.1. Acyl-CoA thioesterases in regulation of coenzyme A (CoASH) levels in 
peroxisomes 
 
As discussed above, the substrates for β-oxidation most likely enter peroxisomes as the 
CoA ester via ABC half transporters, although this has not been proved for all substrates 
(for reviews see [51, 54]). CoASH is also required for the last step of β-oxidation, the 3-
ketoacyl-CoA thiolase reaction, demonstrating a requirement for free CoASH in 
peroxisomes. Little up to date data is available on the intraperoxisomal concentration of 
CoASH, however in the 1980s total peroxisomal CoASH levels were estimated to be 
approximately 700 µM, with un-esterified CoA levels estimated at 230 µM [76, 77]. The 
ratio of esterified to un-esterified CoASH may however vary under different 
physiological conditions such as fed and fasting states, higher levels of slowly oxidized 
carboxylic acids etc. The activity of the ACOT enzymes results in the hydrolysis of acyl-
CoAs, with the concomitant release of the free fatty acid and free CoASH, suggesting a 
role for ACOT enzymes in the regulation of free CoASH levels in peroxisomes. As 
mentioned above, the only two ACOT enzymes identified to be regulated by free CoASH 
are the ACOT8, with an estimated IC50 of 10-15 µM [37], and ACOT12 (with an 
estimated IC50 of about 10 µM) [48], whereas none of the enzymes ACOT3, 4, 5 or 6 
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were inhibited by CoASH even at concentrations of 500 µM. Therefore it appears that 
ACOT8 and ACOT12 act as ‘coenzyme A sensors’ in peroxisomes and may be inhibited 
under conditions of ‘low metabolic activity’, assuming more unesterified CoASH under 
these conditions. However, during conditions when CoASH levels are low or become 
rate-limiting due to sequestration in peroxisomal β-oxidation (such as during fasting or 
possibly fibrate treatment), ACOT8 and ACOT12 would be activated, thus supplying 
CoASH required for the thiolase reaction. It should also be kept in mind that it is not 
clear if the peroxisomal content of unesterified CoASH is readily available since it was 
demonstrated that in isolated peroxisomes, unesterified CoASH appears to be bound to an 
80 kDa protein [78]. This would imply that ACOT8 and ACOT12 may in fact be active 
under most conditions (i.e. not inhibited due to low levels of free CoASH).  
 
A further twist in the regulation of CoASH levels in peroxisomes involves two recently 
identified nudix hydrolase enzymes active on CoASH and CoA derivatives. The first of 
these enzymes is the NUDT7 identified in mouse peroxisomes in 2001 by Gasmi et al 
[79], which acts as a diphosphatase and cleaves CoASH and its derivatives (e.g. acetyl-
CoA) with a Km of ≈240-430 µM, resulting in the production of 3’,5’-ADP and 4’-
phosphopantetheine. NUDT7 homologues have also been cloned from yeast and C. 
elegans. The yeast Nudt7 has a low Km (24 µM) for oxidized CoA (CoASSCoA), which 
is more than ten times lower than the Km for CoASH (Km≈280 µM) [80], suggesting that 
in yeast it removes potentially toxic or non-functional oxidized CoA in peroxisomes. In 
C. elegans, the Km for free CoASH is ≈220 µM and is similar to that of oxidized CoA at 
≈320 µΜ, showing that this enzyme has no real preference for free or oxidized CoA [81]. 
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Similar to the C. elegans enzyme, the mouse NUDT7 does not have a preference for 
oxidized CoA in-vitro as it hydrolyzes free CoA and oxidized CoA with a similar Km of 
around 230 µM [79]. Further investigation by our group suggests that NUDT7 mainly 
metabolizes CoASH esterified to longer chain fatty acids (Reilly et al, manuscript 
submitted). Recently, a further novel peroxisomal nudix hydrolase, RP2p (NUDT19), 
was identified by proteomics analysis of mouse kidney peroxisomes [82]. This enzyme 
also functions as a CoA diphosphatase, with activity toward medium- and long-chain 
acyl-CoAs, branched-chain and bile acid-CoA esters, resulting in the production of 3’,5’-
ADP and acyl-4’-phosphopantetheine. Therefore, NUDT7 and NUDT19 may hydrolyze 
similar substrates, however Nudt7 is mainly expressed in liver whereas Nudt19 is most 
strongly expressed in kidney, but also expressed in several other tissues. It has been 
shown that the peroxisomal membrane forms a permeability barrier for larger cofactors 
such as CoASH [83] and therefore the activity of nudix hydrolases would cleave CoASH 
into two smaller molecules (3’,5’-ADP and 4’-phosphopantetheine) which could then exit 
the peroxisome. Currently there is no information as to possible functions of 3’,5’-ADP 
and 4’-phosphopantetheine in peroxisomes, but possibly 3’,5’-ADP may exit 
peroxisomes via the adenine nucleotide transporter PMP34, (or Ant1 in yeast), which 
have been identified to be involved in the transport of adenine nucleotides across the 
peroxisomal membrane [84, 85]. Similarly, 4’-phosphopantetheine may be recycled for 
CoA synthesis at the outer mitochondrial membrane, as the final two steps involve the 
transfer of an adenyl group from ATP to 4’-phosphopantetheine by phosphopantetheine 
adenylyltransferase to form dephospho-CoA, followed by phosphorylation by 
dephospho-CoA kinase to obtain CoASH (for review see [86]). ADP is also an extremely 
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potent inhibitor of ACOT12 activity [48], which suggests a role for nucleotides in the 
regulation of acetate formation in peroxisomes. However, the surprising finding that the 
nudix hydrolases are more active on acyl-CoA’s rather than with unesterified or oxidized 
CoASH raises questions regarding the in-vivo roles of these enzymes in peroxisomes, in 
particular in relation to the ACOT’s. Hydrolysis of acyl-CoAs by ACOT enzymes will 
result in a free fatty acid, which can be re-esterified to CoASH or transported out of the 
peroxisome, together with a CoASH molecule that can be re-used in peroxisomes. In 
contrast, cleavage of acyl-CoAs by nudix hydrolases will result in catabolism of the 
CoASH molecule, resulting in a fatty acid with the 4’-phosphopantetheine attached (an 
acyl-4’-phosphopantetheine). As yet a possible function for this acyl-4’-
phosphopantetheine molecule is not known. A subject for future studies is obviously to 
determine whether ACOT enzymes are able to hydrolyze acyl-4’-phosphopantetheine 
molecules to release the free acid and 4’- phosphopantetheine.  
 
3.2.2. Involvement of ACOT4 and ACOT8 in regulation of peroxisomal β-oxidation of 
dicarboxylic acids  
 
Dicarboxylic acids were first detected in urine already in 1934 by Verkade and van der 
Lee [87]. In the 1980’s it was established that succinate (a four carbon dicarboxylic acid) 
is present in urine in considerable amounts under normal conditions [88], in addition to 
longer chain dicarboxylic acids (DCA) like adipic acid (C6-DCA), suberic acid (C8-DCA) 
and sebacic acid (C10-DCA), which are increased in urine during conditions of high β-
oxidation activity such as fasting, fat-feeding and diabetes [88-91]. Dicarboxylic acids 
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are formed by omega oxidation of monocarboxylic fatty acids (which are not esterfied to 
CoASH). This occurs by an initial hydroxylation of the ω-carbon, or the ω-1 carbon, by 
microsomal CYP4A enzymes, followed by further oxidations by alcohol and aldehyde 
dehydrogenases, which finally results in formation of a dicarboxylic acid [92]. Under 
normal physiological conditions, ω-oxidation is a minor pathway, accounting for about 5-
10% of fatty acid oxidation, however during conditions such as starvation or diabetes, ω-
oxidation becomes more important [93]. There has been much debate as to whether β-
oxidation of dicarboxylic fatty acids occurs in mitochondria [94] or peroxisomes [72, 95-
98]. However recent studies using human skin fibroblasts showed that the β-oxidation of 
C16 dicarboxylic acids occurs only in peroxisomes [99]. Dicarboxylic acids enter 
peroxisomes, likely as the CoA ester, and are then chain shortened by β-oxidation, 
involving the straight chain acyl-CoA oxidase, the D- and L-specific bifunctional proteins 
and SCPx [99, 100]. Medium- and long-chain dicarboxylic acids are formed from ω-
oxidation as described above, whereas short chain dicarboxylic acids (such as adipic, 
suberic and sebacic acid) are formed from chain shortening of longer chain dicarboxylic 
acids by β-oxidation. The dicarboxylic acids oxidized in peroxisomes are believed to 
originate from mitochondrially produced monocarboxylic acids [91, 98, 101], but 
recently also very long-chain and long-chain monocarboxylic fatty acids have been 
shown to be omega-oxidized to dicarboxylic acids [102, 103]. In peroxisomes, the 
oxidation of C12 dicarboxylic acids results in chain shortening to adipic acid, suberic and 
sebacic acid [95]. Zellweger patients, who are deficient in peroxisomal β-oxidation, also 
excrete adipic acid, suberic and sebacic acid, however, they excrete increased amounts of 
suberic and sebacic acid in urine [104-106] suggesting there is a relative block in β-
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oxidation oxidation of suberic to adipic acid in these patients. It has been proposed that 
peroxisomes oxidize dicarboxylic acids down to adipic acid, but it is unclear if this 
oxidation can proceed to succinic acid. Treatment of rats with adipic acid showed that 
this dicarboxylic acid was not oxidized but was excreted as adipic acid [90], which may 
be due to two factors, one being that the activiation of adipic acid to adipyl-CoA becomes 
rate-limiting as the dicarboxylyl-CoA synthetase does not appear to be active on short 
chain substrates, or secondly that the β-oxidation enzymes may not handle dicarboxylic 
acids of six carbons, and therefore the adipic acid is not β-oxidized [107]. 
 
Characterization of peroxisomal ACOT’s identified two acyl-CoA thioesterases that 
show activity towards dicarboxylic acids, namely ACOT4 and ACOT8. In mouse, 
ACOT4 is a specific succinyl-CoA thioesterase, with some low activity also towards 
glutaryl-CoA [25]. Although the human ACOT4 enzyme has a much broader substrate 
specificity than the mouse ACOT4, the highest activity is found with succinyl-CoA [29]. 
ACOT4 is mainly expressed in kidney and liver in both mouse and human, which are the 
main organs of dicarboxylic acid formation. The identification of these succinyl-CoA 
thioesterases suggests that the oxidation of dicarboxylic acids may continue to succinate, 
by hydrolysis of succinyl-CoA to succinate, which can then be excreted from 
peroxisomes into urine. Alternatively, based on the discussion above that β-oxidation of 
dicarboxylic acids may not proceed beyond adipic acid, the existence of such specific 
succinyl-CoA thioesterases in peroxisomes strongly suggest that succinyl-CoA is formed 
in peroxisomes, possibly by a hitherto unidentified pathway. One possibility is that the 
succinate formed during peroxisomal α-oxidation [108] may be activated to the CoA 
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ester in peroxisomes, which may require hydrolysis for elimination. Succinyl-CoA is 
unlikely to be converted to a carnitine ester in peroxisomes, therefore elimination of 
succinyl-CoA would require the action of ACOT4. Interestingly, ACOT8 (the ‘general’ 
peroxisomal acyl-CoA thioesterase) can also hydrolyze dicarboxylyl-CoAs to the free 
acid and CoASH, but the specificity appears to complement the activity of ACOT4 (Fig 
5) and mainly hydrolyzes longer chain dicarboxylic acids [25]. Given that ACOT8 is 
inhibited by CoASH, it is likely that the oxidation of dicarboxylic acids can proceed to 
produce shorter chain dicarboxylic acids during normal conditions. However, during 
conditions where β-oxidation rates are high and CoASH is sequestered for the thiolase 
reaction, such as during fasting, ACOT8 will be activated, thus producing longer chain 
dicarboxylic acids in peroxisomes. Taken together, these data suggest that ACOT4 and 
ACOT8 are involved in the hydrolysis of short-, medium- and long-chain dicarboxylyl-
CoA esters, respectively, to release dicarboxylic acids for excretion in urine (for an 
overview see Fig. 4). It should be emphasized that a fraction of the dicarboxylic acids 
excreted in the urine in human is in fact conjugated to glycine, a reaction that may 
possibly be carried out by bile acid-CoA:amino acid N-acyltransferase (BAAT) or a 
mitochondrial/cytosolic acyltransferase. 
 
3.2.3 ACOT6 in regulation of methyl branched lipid oxidation 
 
Phytol is formed from chlorophyll in the gut of ruminant animals and phytol is therefore 
ingested in the diet from dairy products. As mammals cannot metabolize phytol directly, 
phytol is converted to phytanic acid in the intestine directly, or is taken up and converted 
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to phytanic acid in the intestine or in other tissues. Phytanic acid (3,7,11,15-
tetramethylhexadecanoic acid) is a 3-methyl branched fatty acid and therefore cannot 
undergo β-oxidation directly. Therefore, phytanic acid is first activated to phytanoyl-CoA 
and subsequently metabolized to pristanic acid by a process known as alpha-oxidation 
(for review see [108]). Mutations in one of the genes involved in this process, phytanoyl-
CoA hydroxylase (PHYH), results in Refsum disease (for review on phytanic acid and 
human disease see [109]). This α-oxidation process occurs in peroxisomes by a dedicated 
set of enzymes, although it has been disputed if the final enzymatic step by a fatty 
aldehyde dehydrogenase also occurs in peroxisomes [110]. Recently however, alternative 
splicing of the fatty aldehyde dehydrogenase was shown to result in a dual localization in 
the endoplasmic reticulum and peroxisomes, indicating that all enzymes required for α-
oxidation are indeed localized in peroxisomes [111]. The conversion of a 3-methyl 
branched fatty acid (phytanic acid) to a 2-methyl branched fatty acid (pristanic acid 
(2,6,10,14-tetramethylpentadecanoic acid)) results in a carboxylic acid that can then 
undergo β-oxidation. However, the β-oxidation of 2-methyl branched substrates is further 
complicated by the stereo-specificity of the substrate. Only 2S isomers of pristanic acid 
can undergo β-oxidation and therefore the 2R isomer needs to be converted to the 2S 
isomer, in a reaction catalyzed by the enzyme alpha-methylacyl-CoA racemase 
(AMACR) [112, 113]. As this enzyme contains both a mitochondrial targeting signal and 
a peroxisomal type 1 targeting signal, the protein localizes in both peroxisomes and 
mitochondria [114]. AMACR deficiency results in adult onset sensory motor neuronal 
and liver abnormalities [115, 116]. The 2S isomer of pristanoyl-CoA undergoes β-
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oxidation in peroxisomes by the sequential reactions of branched chain acyl-CoA oxidase 
(ACOX3), the D-bifunctional protein and SCPx.  
 
We recently identified an acyl-CoA thioesterase (ACOT6) that only hydrolyzes CoA 
esters of phytanic acid and pristanic acid, and can therefore function as an auxiliary 
enzyme in the metabolism of alpha-methyl branched fatty acids [27]. This enzyme has a 
Km of ≈24 µM for pristanoyl-CoA, and is localized in peroxisomes. The specific activity 
of phytanoyl-CoA/pristanoyl-CoA thioesterase was very high in highly purified mouse 
liver peroxisomes, compared to the activity with myristoyl-CoA, and an anti-ACOT6 
antibody immunoprecipitated essentially all of the phytanoyl/pristanoyl-CoA activity, but 
none of the myristoyl-CoA thioesterase activity, showing that ACOT6 is the main acyl-
CoA thioesterase in peroxisomes that hydrolyzes these branched chain CoA esters [27]. 
Surprisingly, this mRNA is most strongly expressed in white adipose tissue, but it was 
shown to be strongly co-expressed with Acox3 in most tissues, which is the presumed 
rate-limiting enzyme involved in the β-oxidation of pristanoyl-CoA. White adipose tissue 
is the main organ involved in the storage of pristanic acid, and in rats, approx 10% of 
ingested pristanic acid is found in white adipose tissue and liver one week after treatment 
[117, 118]. The identification of an ACOT specific for branched chain acyl-CoA esters in 
white adipose tissue suggested an unexpected role for ACOT6 in this tissue. As stated 
above, the 2R isomer of pristanoyl-CoA must be converted to the 2S isomer before it can 
be β-oxidized. Expression analysis showed that Amacr mRNA levels are very low in 
white adipose tissue, suggesting that conversion of the 2R-isomer to the 2S-isomer may 
be rate-limiting and thereby hamper β-oxidation of pristanic acid [27]. Strikingly, 
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ACOT6 does not show stereo-specificity for the 2R and 2S isomers and can therefore 
hydrolyze both isomers of pristanoyl-CoA. The current hypothesis is therefore that the 
2R isomer would be hydrolyzed by ACOT6 in white adipose tissue, due to inadequate 
activity of AMACR, to release the free acid and CoASH, and the 2R pristanic acid may 
exit the peroxisome to be re-activated to the CoA ester in the cytosol and esterified into 
triacylglycerols. Alternatively, the 2R-isomer could enter the circulation to be transported 
back to the liver where it can be racemized by the AMACR to the 2S isomer, thus 
allowing its degradation by peroxisomal β-oxidation (Fig. 6). Pristanic acid undergoes 
three rounds of β-oxidaiton in peroxisomes, resulting in the production of 4,8-
dimethylnonanoyl-CoA (DMN-CoA). This DMN-CoA can then be hydrolyzed to free 
DMN acid by ACOT8 or ACOT5 (the latter being most highly expressed in white 
adipose tissue), since both enzymes show appreciable activity towards DMN-CoA [26, 
37]. However, it may be that ACOT8 is most significant in this hydrolysis as it has a Km 
of 5 µM for this substrate. Alternatively, DMN can be esterified to carnitine by CROT (in 
liver, intestine and kidney), and transferred to mitochondria for further degradation to 
2,6-dimethylheptanoyl-CoA [70].  
 
3.2.4. Acyl-CoA thioesterases and synthesis of polyunsaturated fatty acid  
Docosahexanoic acid (DHA) (C22:6n-3) is the major n-3 polyunsaturated fatty acid 
(PUFA) in adult mammalian brain and retina and is found in amino phospholipids of cell 
membranes. It is now well established that DHA formation involves a combined reaction 
sequence of desaturation and elongation with a final step of β-oxidaiton in peroxisomes, 
in which C24:6n-3 is β-oxidized to C22:6n-3 and C24:5n-6 oxidized to C22:5n-6 (for 
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review see [119]). Fibroblasts from Zellweger patients cannot produce DHA [120, 121], 
confirming that the final step of DHA formation takes place in peroxisomes. The DHA is 
then incorporated into phospholipids in the endoplasmic reticulum after it’s synthesis in 
peroxisomes. The enzymes involved in β-oxidation of C24:6n-3 to C22:6n-3 have been 
elucidated and involves the straight chain acyl-CoA oxidase (ACOX1), the D-
bifunctional protein and both the 3-ketoacyl-CoA thiolase and SCPx [120]. Although, to 
date no specific acyl-CoA thioesterase enzyme has been identified in the metabolism of 
DHA in peroxisomes, acyl-CoA thioesterase activity towards C22:6n-3 and C24:6n-3 has 
been identified in purified mouse kidney peroxisomes and it was suggested that DHA 
could be transported to the endoplasmic reticulum as the free acid [122]. Given the wide 
substrate specificity of ACOT8 and its ubiquitous tissue expression, it is likely that this 
enzyme can hydrolyze DHA to the free acid in peroxisomes, and work is currently 
underway in our laboratory to elucidate which ACOT is involved in this process. 
 
4. The acyltransferases involved in conjugation (amidation) of bile acids and fatty 
acids in peroxisomes 
 
4.1 The acyl-CoA:amino acid N-acyltransferase gene cluster 
 
There is a further gene cluster related to the Type-I Acots (discussed in Section 2.1.1), 
which contains three distinct genes localized on chromosome 4 B3 in mouse (Fig. 7). 
These genes are named bile acid-CoA:amino acid N-acyltransferase (BAAT) and acyl-
CoA:amino acid N-acyltransferase 1 and 2 (ACNAT1 and 2), which show approximately 
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40% sequence identity to the ACOT 3, 4, 5 and 6 at protein level. The Baat and the 
Acnats show about 55% sequence identity to each other, whereas Acnat1 and Acnat2 
show 96% sequence identity to eachother. All three of these gene products appear to be 
localized in peroxisomes, although there is still some confusion regarding the cellular 
localization of BAAT (see below). The corresponding gene “cluster” in humans only 
contain two genes, one coding for BAAT, and an apparent ACNAT pseudogene, which 
contains in-frame stop codons and therefore would not code for a functional protein, 
although it contains a peroxsomal targeting signal of -SKL (Fig. 7).  
 
4.1.1. Peroxisomes contain a bile-acid conjugating enzyme catalyzing the terminal step in 
bile acid synthesis. 
 
It is well established that the conjugation (or amidation) of bile acids occurs in 
peroxisomes, resulting in the production of bile salts that are excreted into bile and stored 
in the gallbladder. This final step in the conversion of cholesterol to bile acids involves 
one round of β-oxidation of the side-chain of the C27 bile-acid precursors 
trihydroxycoprostanoyl-CoA and dihydroxycoprostanoyl-CoA to chenodeoxycholoyl-
CoA and choloyl-CoA (the C24 bile acids) [123-127]. These C24 bile acids are then 
conjugated (or amidated) to glycine or taurine (depending on the species) by the enzyme 
bile acid-CoA:amino acid N-acyltransferase (BAAT) [128-132]. The intracellular 
localization of BAAT has been reported to be both cytosolic and peroxisomal. In the 
1960’s, bile acid conjugation activity was reported in the lysosomal fraction (or possibly 
the peroxisomal fraction) of human liver [133] and was later identified in the microsomal 
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and peroxisomal fractions of rat liver homogenates [134]. Further studies showed that 
BAAT activity is distributed in microsomes, cytosol or peroxisomes in rat, mouse and 
human [130, 134-139]. In view of the data showing BAAT activity in 
cytosol/microsomes and peroxisomes, it has been hypothesized that two pathways for 
amidation of bile acids exist, one pathway in peroxisomes for the amidation of the de-
novo synthesized primary bile acids, cholic acid and chenodeoxycholic acid, and a 
second pathway in the cytosol for the re-amidation of deconjugated primary and 
secondary bile acids recycled back to the liver via the enterohepatic circulation. The 
human very long-chain acyl-CoA synthetase homolog 2 (VLCS), also known as BACS 
(bile acid-CoA synthetase), was shown to activate the primary bile acids cholate [140] 
and chenodeoxycholate, and also the secondary bile acids deoxycholate and lithocholate 
[141] in the cytosol, also suggesting two pathways of bile acid metabolism, with the 
cytosolic pathway being responsible for reactivation/reconjugation of recycled bile acids. 
Recently, recombinantly expressed human BAAT has also been shown to conjugate fatty 
acids (mainly long-chain acyl-CoAs) to glycine and taurine [131] (Fig. 8). Mouse, rat and 
human BAAT proteins show approx 70% sequence identity to each other, which all 
contain a carboxyterminal serine, glutamine, leucine sequence (-SQL). This tripeptide is a 
variant of the consensus peroxisomal targeting signal of serine, lysine, leucine (-SKL), 
known to target proteins to peroxisomes [142]. Studies on the cellular localization of 
BAAT using green fluorescent fusion proteins showed that this fusion protein was 
entirely cytosolic in human skin fibroblasts [131], which was confirmed in other studies 
[143]. However, in rat and human primary hepatocytes, BAAT was localized in 
peroxisomes [143], suggesting that targeting of non-consensus PTS1-containing proteins 
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may be more efficient in liver cells than for example in fibroblasts. In this study by 
Pellicoro, co-transfection of human BAAT and a peroxisomal marker DSRed-SKL in rat 
primary hepatocytes, resulted in a cytosolic localization of BAAT, suggesting that the 
peroxisomal import machinery becomes saturated with DSRed-SKL and therefore 
targeting of BAAT, which contains a non-consensus targeting signal of –SQL, is 
inefficient. As a result, in liver where BAAT is highly expressed, the protein is likely to 
be mainly peroxisomal and involved in the amidation of de-novo synthesized bile acids 
as discussed in a recent review on peroxisomes and bile acid biosynthesis [144]. 
However, it still cannot be excluded at this stage that BAAT has a dual localization in 
cytosol and peroxisomes, and that this dual localization may be affected by 
pharmacological treatment [135]. Thus, the mechanism for targeting of BAAT to 
peroxisomes is still not fully understood and needs further consideration. 
 
The catalytic triad of BAAT has been elucidated and involves a cysteine, aspartic acid 
and histidine, similar to the Type I ACOT enzymes, however the ACOTs contain an 
active site serine in place of the cysteine in BAAT [131, 145]. Interestingly, the ACNATs 
also contain an active site serine, however this serine is localized in a SerXaaSerXaaGly 
motif and not in a GlyXaaSerXaaGly motif common to the ACOTs [146]. A mutation in 
the BAAT protein (and tight junction protein 2) in an Amish population resulted in 
familial hypercholanemia, which is characterized by elevated serum bile acid 
concentrations, itching and fat malabsorption [147].  
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4.1.2. Peroxisomes contain two putative acyl-CoA:amino acid N-acyltransferases that 
conjugate fatty acids and possibly other carboxylic acids 
 
Two further genes related to Baat have been identified in mouse (Fig. 7), however as 
stated earlier, the ACNAT gene in human is a pseudogene. These mouse genes encode 
two novel acyl-CoA:amino acid N-acyltransferases (ACNAT1 and ACNAT2) and one of 
these enzymes, ACNAT1, was recently characterized [146]. These two ACNAT proteins 
show approx 55% sequence identity to BAAT, with 95% sequence identity to each other. 
ACNAT1 and ACNAT2 both contain a consensus peroxisomal targeting signal of -SKL 
at the carboxyterminal end, which localizes the proteins to peroxisomes [146] (and Reilly 
et al, unpublished results). Acnat1 mRNA is mainly expressed in liver and kidney in 
mouse, and characterization of recombinant ACNAT1 protein identified it as a 
peroxisomal acyltransferase involved in conjugation of mainly very long-chain and long-
chain fatty acids (C16-C24) to taurine, with some very low activity with bile acids [146]. 
The identification of this taurine conjugating activity in peroxisomes suggests a possible 
novel pathway for metabolism/excretion of long-chain fatty acids as taurine conjugates 
(Fig. 8). Interestingly, the group of Cravatt recently identified taurine-conjugated fatty 
acids (N-acyltaurines) as a novel class of endogenous signaling lipids. These N-
acyltaurines (NATs) were first detected by global metabolic profiling in the fatty acid 
amide hydrolase (FAAH) knockout mouse model in brain, spinal cord, testes and liver 
[148, 149]. The FAAH is an integral membrane protein that degrades endogenous 
signaling lipids [150], thereby regulating in-vivo levels of signaling molecules. Notably, 
these taurine conjugates were mainly of C16-C26 in chain length, similar to the chain 
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length specificity for ACNAT1. In wild-type FAAH animals, these NATs were detected 
at approx 20-50 pmol/g tissue, however, in the FAAH knockout mouse model, levels of 
these NATs rose to nmol/g levels. Taurine conjugates of unsaturated long-chain fatty 
acids such as arachidonyltaurine (C20:4 taurine) were also detected in liver and kidney at 
concentrations of 20 pmol/g in liver and 157 pmol/g in kidney, respectively. 
Interestingly, arachidonyltaurine was shown to activate transient receptor potential (TRP) 
channels, TRPV1 and TRPV4, which are expressed in kidney, with an EC50 value of 28 
µM and 21 µM respectively, suggesting a role for taurine conjugated fatty acids in cell 
signalling [151]. However, arachidonoyl-CoA is a poor substrate for ACNAT1, 
suggesting that there is one or more acyltransferases that can conjugate this fatty acid to 
taurine, possibly ACNAT2 for which there is as yet no report with respect to it’s substrate 
specificity. The TRPV1 and TRPV4 calcium channels are proposed to play roles in 
regulation of blood pressure and osmotic sensation [152], however further physiological 
studies are warranted to elucidate the role of ACNAT1 (or ACNAT2) in these processes.  
 
The identification of N-acyltaurines (especially saturated N-acyltaurines) in brain raises 
the question if these molecules are formed in-situ in brain or could be synthesized by 
ACNAT1 in liver and kidney, and be transported to the brain via the bloodstream. We 
have detected long chain NATs in serum, which under normal conditions are detected at 
low levels, however during prolonged fasting, and in particular in PPARα-knockout 
mice, strongly elevated levels can be detected (Reilly et al, unpublished observation), 
suggesting that amidation of fatty acids may provide an important excretory pathway for 
fatty acids in bile or urine under some conditions. NATs are also substrates for and 
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FAAH can hydrolyze NATs back to the free acid plus taurine, thus regulating in-vivo 
levels of NATs [149].  
 
Peroxisomes are also associated with the metabolism of certain xenobiotics [49] and the 
β-oxidation of very long chain acyl-CoAs, prostaglandins, and bile acids, all of which are 
substrates for taurine (or glycine) conjugation. Searches in the literature showed that 
taurine and/or glycine conjugation of a number of physiological substrates and xenobiotic 
compounds, including a number of pharmaceutical drugs, involves partial β-oxidation 
followed by conjugation to taurine or glycine, and subsequent excretion into urine or bile. 
However, there are large species differences in the taurine conjugates identified, with 
taurine conjugates of cerivastatin metabolites identified in dog [153], taurine conjugated 
prostaglandins identified in rat [154] and an unusual taurine conjugate of ganglioside 
GM2 identified in Tay-Sachs brain [155].  These aspects should be interesting to explore 
in future studies in relation to species-specific expression and substrate specificities of 
these acyltransferases that may also have very important functions in drug metabolism. 
 
The substrate specificity of ACNAT2 has not yet been characterized, but as this enzyme 
is also peroxisomal and shows 95% sequence identity to ACNAT1, we speculate that this 
enzyme also functions as a taurine conjugator in peroxisomes, with the likely substrates 
being unsaturated fatty acids and possibly xenobiotics. As stated above, taurine 
conjugates of unsaturated fatty acids have been identified in brain, liver and kidney [148, 
151], however ACNAT1 only conjugates saturated fatty acids.  
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5. Regulation of peroxisomal acyl-CoA thioesterases and acyltransferases   
 
5.1. Regulation of Acots and acyltransferases in peroxisomes 
 
Currently, there is little information available on regulation of peroxisomal ACOT 
enzymes, however all are targets of the PPARα. Fibrates belong to a group of compounds 
that act as ligands for the PPARα and treatment of rodents with these compounds results 
in an increase in the number and size of peroxisomes and in an increase in peroxisomal β-
oxidation [4]. The enzymes of the straight chain β-oxidation pathway are strongly 
upregulated via fibrate treatment, whereas the enzymes in branched chain oxidation are 
unaltered by such treatment [156]. In line with an increase in peroxisomal β-oxidation, 
Acot3, 4, 5 and 6 are all upregulated by fibrate treatment at both protein and mRNA 
levels [25-27]. This upregulation is dependent on the PPARα, as upregulation was of 
Acot3, 4, 5 and 6 ablated in the PPARα knockout mouse model. Similarly, Acot8 is also 
upregulated by fibrates in a PPARα-dependent manner [37]. During fasting conditions, 
also known to result in increased PPARα activation and upregulation of peroxisomal β-
oxidation, only Acot3, Acot4, Acot5 and Acot8 are upregulated at mRNA level [25, 26, 
37]. At present there are no data available on quantitative changes in Acot12 mRNA in 
response to fibrate treatment, but ACOT12 activity is increased in the peroxisomal 
fraction (per gram of liver tissue) and in the cytosolic fraction, suggesting that Acot12 
expression is indeed increased in response to fibrates [46]. Recently, a list of genes 
compiled from array data of PPARα wild-type and PPARα-null mice, showed that 
Acot12 is regulated by fasting and Wy-14,643 in mouse liver [157]. Ebisuno et al also 
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showed an increase of ACOT12 activity in early diabetic conditions, and by cholesterol 
and clofibrate feeding, but no change was observed in chronic diabetes [158]. In 
summary, the findings that the expression of all peroxisomal ACOT’s is increased in 
response to PPARα activation suggests that these enzymes do promote β-oxidation in 
peroxisomes. Furthermore, Acot3 was shown to be upregulated 13-fold in mouse liver 
following a chemical knockout of the pantothenate kinase (PanK), the rate limiting 
enzyme in CoA biosynthesis [159]. Interestingly, the cytosolic and mitochondrial Acots 
(Acot1 and Acot2 respectively) were also upregulated over 40-fold at mRNA level in the 
PanK knockout, suggesting that all the thioesterases are indeed important enzymes in 
regulating hepatic CoASH levels. The mouse ACOT3 was also recently identified in a 
proteomic study of mitochondrial phosphoproteins, as a phosphorylated protein, with 
phosphorylation on serine 67 of ACOT3 (serine 56 in ACOT4, 5 and 6) [160]. 
Interestingly, this serine is conserved in all mouse peroxisomal ACOTs but not in human 
ACOT4, suggesting a possible species-specific phosphorylation of mouse peroxisomal 
ACOT’s.  
 
As Acnat1 and Acnat2 have been identified very recently, there is currently little 
information on their regulation, but Acnat1 does not appear to be regulated by fibrate 
treatment, fasting or bile acid treatment (unpublished observation). In contrast, Acnat2 is 
strongly upregulated by treatment of mice with fibrates and statins (Reilly et al 
unpublished results). In mouse, Baat mRNA and activity has been shown to be 
downregulated by fibrate treatment [135, 139], but in rat treatment with clofibrate results 
in an increased activity of BAAT in peroxisomes in male mice, but the activity is 
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decreased in female mice [135]. Baat mRNA is upregulated by cholestyramine (a bile 
acid binding resin) treatment in mouse liver [139], whereas in rat, BAAT activity is 
unchanged by cholestyramine treatment [135], showing a distinct species difference. Baat 
is regulated by the farnesoid X receptor (FXR) in the rat via an inverted repeat 1 (IR-1) 
element located in the first intron of the gene and Baat mRNA levels were increased in 
rats following treatment with a synthetic FXR ligand [161]. Baat expression is also 
regulated by the hepatocyte nuclear factor 4 alpha (HNF-4α) via a response element in 
the promoter and expression of the Baat mRNA is not detectable in the HNF-4α 
knockout mouse, resulting in markedly elevated levels of unconjugated bile acids in 
gallbladder in this knockout model [162]. Recently Baat expression was shown to be 
reduced in sepsis in rat via the retinoid X receptor-alpha [163]. Taken together, the 
profound regulation of the ACOTs and acyltransferase genes by various nuclear receptors 
support the notion that these enzymes have important regulatory functions in different 
metabolic pathways. 
 
6.  Concluding remarks and perspectives 
 
The identification of a family of acyl-CoA thioesterases/acyltransferases in peroxisomes 
has led to the identification of novel metabolic pathways for fatty acids in this organelle. 
It is hoped that future studies using knockout mouse models and knockdown studies will 
help to identify precise roles for these enzymes in peroxisomal lipid metabolism, which 
could lead to identification of patients with new previously uncharacterized peroxisomal 
disorders. 
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Figure Legends 
 
Figure. 1. The reactions catalyzed by acyl-CoA thioesterases (ACOTs) and acyl-
CoA:amino acid N-acyltransferases (ACNAT and BAAT).  ACOTs hydrolyze the 
CoA ester of various fatty acids into the free fatty acid + coenzyme A (CoASH). The 
substrate shown is stearoyl-CoA (C18-CoA) but can be long-chain, medium-chain, short-
chain, branched-chain, bile acid-CoAs or dicarboxylyl-CoAs, depending on the ACOT 
enzyme involved. (B) The reaction catalyzed by acyl-CoA:amino acid N-acyltransferase 
(ACNAT) is the conjugation (or amidation) of fatty acids (long-chain and very long-
chain) to taurine, resulting in the production of an N-acyltaurine. The substrate shown is 
stearoyl-CoA (C18-CoA) (C) The bile acid-CoA:amino acid N-acyltransferase (BAAT) 
catalyzes the conjugation (amidation) of bile acids to glycine or taurine, resulting in a 
conjugated bile acid. Choloyl-CoA is shown as the substrate, with glycine as the 
acceptor, resulting in the formation of choloylglycine. Human BAAT can also conjugate 
fatty acids to glycine or taurine as shown in the reaction in (B) above. 
 
Figure 2. The Type-I acyl-CoA thioesterase gene cluster in human and mouse. The 
Type-I human acyl-CoA thioesterases are localized in a cluster on human chromosome 
14q24.3, encoding two cytosolic, one mitochondrial and one peroxisomal enzyme 
(ACOT4). The peroxisomal ACOT4 contains a carboxyterminal –PKL, which functions 
as a peroxisomal targeting signal. In mouse, a similar cluster is found on chromosome 12 
D3, containing four peroxisomal Acots (Acot3, 4, 5 and 6), one mitochondrial and one 
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cytosolic gene. Each of the four peroxisomal ACOTs contain a peroxisomal targeting 
signal of –CRL, -AKL, or –SKL.  
 
Figure 3. Routes for excretion of fatty acids from peroxisomes. Very long-chain fatty 
acids (VLCFA), bile acid intermediates, methyl branched fatty acids and dicarboxylic 
acids enter the peroxisome, likely as the CoA ester, via ABC half transporters. ABCD1 
transports VLCFAs into peroxisomes and ABCD3 may be involved in transport of bile 
acid-CoA intermediates and branched chain CoA esters. It is not yet known which ABC 
protein is involved in transport of dicarboxylyl-CoA esters. These CoA esters then 
undergo β-oxidation in peroxisomes, involving a dehydrogenation (catalyzed by an acyl-
CoA oxidase), hydration/dehydrogenation (catalyzed by a bifunctional enzyme) and a 
thiolytic cleavage (catalyzed by a thiolase). CoASH is required for the thiolase reaction, 
resulting in a chain-shortened CoA ester plus acetyl-CoA or propionyl-CoA, depending 
on the substrate. There are three potential pathways for these chain shortened products; 
esterification to carnitine catalyzed by carnitine acyltransferases (CRAT and CROT), 
hydrolysis to the free acid by acyl-CoA thioesterases (ACOTs) or to the acyl-4’-
phosphopantetheine by nudix hydrolases (NUDT7 or NUDT19), or conjugation 
(amidation) to glycine or taurine by the bile acid-CoA:amino acid N-acyltransferase 
(BAAT), or to taurine by the acyl-CoA:amino acid N-acyltransferases (ACNAT1 and 
ACNAT2). These products may then be transported to mitochondria for further oxidation 
or excreted directly in urine or bile. 
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Figure 4. Schematic representation of the roles of ACOTs, carnitine acyltransferases 
and nudix hydrolases in peroxisomal α- and β-oxidation. Very long-chain fatty acids 
(VLCFA) are transported into the peroxisome via the ABCD1 transporter and undergo β-
oxidation to produce chain-shortened acyl-CoAs, with the concomitant release of acetyl-
CoA. These very long chain acyl-CoAs can be hydrolyzed to the free fatty acid and 
CoASH by ACOT3, or alternatively may be further β-oxidized to medium chain acyl-
CoAs (MC-CoA). ACOT5 and CROT are both active on medium chain acyl-CoAs, 
resulting in production of the free acid (MCFA) or carnitine ester (MC-carn), depending 
on the tissue involved [28]. These long chain/medium chain fatty acids or carnitine esters 
may be transported to the mitochondria for further oxidation. Long chain dicarboxylic 
acids (LC-DCA) are transported into the peroxisome, likely as the CoA ester through an 
as yet unidentified ABCD transporter and undergo β-oxidation, resulting in medium 
chain dicarboxylyl-CoAs (MC-DCA), which are substrates for ACOT8, or alternatively 
are further β-oxidized to a C4 succinyl-CoA. As succinyl-CoA cannot be converted to a 
carnitine ester, it is hydrolyzed by the action of ACOT4, resulting in production of 
succinate, which is excreted in urine. The acetyl-CoA produced by β-oxidation can be a 
substrate for either the short chain carnitine acetyltransferase (CRAT) or the short chain 
acyl-CoA thioesterase (ACOT12), resulting in production of the free acid or carnitine 
ester, depending on the tissue involved [28]. The acetate will go the cytosolic pool of 
acetate, whereas the acetylcarnitine will be transported to the mitochondria for further 
oxidation. The metabolism of CoASH in peroxisomes occurs by the action of Nudix 
hydrolases, NUDT7 and NUDT19, which hydrolyze free CoASH to 3’,5’-ADP and 4’-
phosphopantetheine. Recent data also indicates that these enzymes hydrolyze bile acid-
 56 
CoA esters, long-chain, medium-chain and short-chain acyl-CoAs to 3’,5’-ADP and acyl-
4’-phosphopantetheine, however the physiological significance of this activity is not yet 
fully understood. For simplicity, only the reaction of NUDT7 and NUDT19 with free 
CoA is shown. The substrates and the enzymes are involved are colour-coded. 
 
Figure 5. ACOT4 and ACOT8 both hydrolyze dicarboxylyl-CoA esters but with 
different specificities. Thioesterase activity of recombinantly expressed ACOT4 and 
ACOT8 were measured with short and medium chain dicarboxylyl-CoAs at 25 µM. Data 
are shown as mean ± S.E.M. Figure reproduced with permission from J. Biol. Chem. 
[25].  
 
Figure 6. The role of ACOT6 in methyl branched acyl-CoA metabolism in 
peroxisomes. Phytanoyl-CoA enters peroxisomes, possibly through the ABCD3 
transporter. The α-oxidaiton of phytanoyl-CoA to pristanoyl-CoA results in conversion 
of a 3-methyl branched fatty acid to a 2-methyl branched fatty acid, which is then a 
substrate for β-oxidation. Pristanoyl-CoA undergoes 3 cycles of β-oxidation, resulting in 
the production of dimethylnonanoyl-CoA (DMN-CoA), which can either be esterified to 
carnitine by CROT, or alternatively hydrolyzed to the free acid by ACOT8 or ACOT5, 
and be further oxidized in mitochondria. Propionyl-CoA and acetyl-CoA are produced 
from the β-oxidation of methyl branched fatty acids, which will be substrates for CRAT 
or ACOT12. The acetate/propionate will go the cytosolic pool, whereas the 
acetylcarnitine/propionylcarnitine will be transported to the mitochondria for further 
oxidation. ACOT6 can hydrolyze pristanoyl-CoA and phytanoyl-CoA directly to the free 
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acid, allowing for esterification of pristanic and phytanic into triglycerides (TAG). 
ACOT6 is active in white adipose tissue to hydrolyze the 2R isomer of pristanoyl-CoA to 
pristanic acid, which can then go to liver to be converted to the 2S isomer by the 
AMACR (see section 3.1.4 for further details) and be β-oxidized. Pristanic and phytanic 
acid are ligands for the PPARα [164], thus ACOT6 may also function in ligand supply 
for this nuclear receptor, as discussed in [27]. 
 
Figure 7. The acyltransferase gene cluster in human and mouse. Human contains an 
acyltransferase gene cluster localized on chromosome 9q31.1, encoding for the bile acid-
CoA:amino acid N-acyltransferase (BAAT) enzyme and a further acyl-CoA:amino acid 
N-acyltransferase (ACNAT) pseudogene. BAAT contains a variant of the peroxisomal 
targeting signal –SQL, whereas the ACNAT pseudogene contains –SKL. The ACNAT 
pseudogene contains in-frame stop codons that will not translate into a functional protein. 
In mouse, a related gene cluster on chromosome 4 B3 contains three acyltransferase 
genes Baat, Acnat1 and Acnat2. BAAT contains a variant of the peroxisomal targeting 
signal, ending –SQL, whereas ACNAT1 and ACNAT2 contain canonical peroxisomal 
targeting signals –SKL at their carboxyterminal ends. 
 
Figure 8. Schematic representation of the roles of acyltranserases in peroxisomal 
lipid metabolism. The final step in the formation of the primary bile acids, choloyl-CoA 
and chenodeoxycholoyl-CoA involves one cycle of β-oxidation in peroxisomes, resulting 
in the formation of a C24 bile acid from a C27 bile acid trihydroxycoprostanoyl-CoA 
(THCA-CoA) or dihydroxycoprostanoyl-CoA (DHCA-CoA), with the concomitant 
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release of propionyl-CoA. These C27 bile acids may enter the peroxisome via the 
ABCD3 transporter. The conjugation (amidation) to glycine or taurine is carried out by 
BAAT to produce a glyco- or tauro-conjugated bile acid, which is then excreted in bile. 
ACOT8 can also hydrolyze the CoA esters of choloyl-CoA and chenodeoxycholoyl-CoA, 
resulting in free bile acids cholic acid (CA) and chenodeoxycholic acid (CDCA), 
however the physiological function of this enzyme in bile acid synthesis is not yet clear. 
Very long-chain fatty acids (VLCFA) are transported into the peroxisome via the ABCD1 
transporter and undergo β-oxidation, to produce chain-shortened acyl-CoAs, with the 
concomitant release of acetyl-CoA. These very long chain and long chain acyl-CoAs are 
substrates for conjugation (amidation) to taurine by ACNAT1, resulting in the production 
of an N-acyltaurine. These N-acyltaurines can then be excreted in urine or bile, or be 
transported in blood to other tissues. N-acyltaurines have also been shown to activate the 
transient receptor potential ion channels TRPV1 and TRPV4 [151]. Human BAAT has 
also been shown to conjugate long-chain and very long-chain acyl-CoAs to glycine and 
taurine [131], but it is not known if the mouse or rat BAAT have this activity. The 
propionyl-CoA or acetyl-CoA produced by β-oxidation can be substrates for either the 
short chain carnitine acetyltransferase (CRAT) or the short chain acyl-CoA thioesterase 
(ACOT12), resulting in production of the free acid or carnitine ester, depending on the 
tissue involved [28]. The acetate/propionate will go the cytosolic pool, whereas the 
acetylcarnitine/propionylcarnitine will be transported to the mitochondria for further 
oxidation.  
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Table I. Characteristics of peroxisomal acyl-CoA thioesterases and acyltranserases 
identified in mouse. The peroxisomal targeting signal shown as a tripeptide at the 
carboxyterminal end is indicated. Acot: acyl-CoA thioesterase; Baat: bile acid-
CoA:amino acid N-acyltransferase; Acnat: acyl-CoA: amino acid N-acyltransferase; 
Prox: proximal; WAT: white adipose tissue 
 
 
 
Gene 
 
Carboxy  
terminal 
sequence 
Previous 
nomenclature 
and aliases 
Substrate (CoA 
ester) 
[reference] 
Chromosome 
and 
accession 
number 
Tissue 
expression 
Acot3 -AKL PTE-Ia Long chain [26] 12 D3 
NP_599007 
Kidney 
Acot4 -CRL PTE-Ib, Pte2b
  
Succinyl, glutaryl 
[25] 
12 D3 
NP_599008 
Liver, 
kidney 
Acot5 -AKL PTE-Ic Medium chain [26] 12 D3 
NP_663419 
Brain, 
WAT 
Acot6 -SKL PTE-Id Pristanoyl/phytanoyl 
[27] 
12 D3 
NP_766168 
WAT, 
Kidney, 
Liver 
Acot8 -SKL PTE-2, hTE, 
hACTEIII, 
PTE1 
All tested CoA 
esters [25, 37, 38] 
2 H3 
NP_573503 
Ubiquitous 
– mainly 
Prox. 
Intestine, 
Kidney, 
Liver 
Acot12 -SVL CACH-1, 
MGC105114 
mCACH-1, 
CACH 
Short chain 
[44] 
13 C3 
NP_083066 
Prox. 
Intestine, 
Liver, 
Kidney 
Baat -SQL BACAT, BAT Bile acids 
[128] 
4 B3 
NP_031545 
Liver 
Acnat1 -SKL  Long chain/very 
long chain [146] 
4 B1 
ABE98441 
Liver, 
Kidney 
Acnat2 -SKL  Unknown 
 
4 B1 
(not yet 
available) 
Kidney 
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Table II. Characteristics of peroxisomal acyl-CoA thioesterases and acyltranserases 
identified in human. The peroxisomal targeting signal shown as a tripeptide at the 
carboxyterminal end is indicated. Acot: acyl-CoA thioesterase; Baat: bile acid-
CoA:amino acid N-acyltransferase. 
 
Gene 
 
Carboxy  
terminal 
sequence 
Previous 
nomenclature 
and aliases 
Substrate 
(CoA ester) 
[reference] 
Chromosome 
and accession 
number 
Tissue 
expression 
ACOT4 -PKL PTE-1b, PTE-
2b,hPTE-1 
Succinyl, 
glutaryl, 
long chain 
[29] 
14q24.3 
NP_689544 
Kidney, 
Liver 
ACOT8 -SKL PTE-2, hTE, 
hACTEIII, 
PTE1 
**medium 
and long 
chain [32]   
20q12-q13.1 
NP_005460 
Ubiquitous# 
ACOT12 -SKF * CACH-1, 
MGC105114 
mCACH-1, 
CACH 
Short chain 
[45] 
5q14.1 
NP_570123 
Liver# 
BAAT -SQL BACAT, BAT Bile acids, 
long 
chain/very 
long chain 
[129, 131] 
9q22.3 
NP_001692 
Liver, 
Gallbladder 
mucosa 
 
* Peroxisomal localization not confirmed 
 
 ** Activity only tested with saturated acyl-CoA. As the mouse and rat enzymes are 
active on a broad range of acyl-CoAs, it is likely that the human enzyme has a similar 
broad substrate specificity.  
# Based on GEO Profiles (http://www.ncbi.nlm.nih.gov) 
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